Floatz logo

HYROGEN PEROXIDE

Multiple Sclerosis

Tehran University of Medical SciencesSmall moleculeN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

HYROGEN PEROXIDE is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Basal Cell CarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Squamous Cell Carcinoma of Skin DifferentiatedDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →